Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline. So What: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August 10, 2023 through June 25, 2025 (the "Class Period"). Investor Deadline:  Investors who purchased or acquired Altimmune securities during the Class Period may, no l ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc., ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action on behalf of investors that bought securities between August 10, 2023, and June 25, 2025, inclusive (the “Class Period”). Altimmune investors have until October 6, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

涉及的行业或公司 * 公司为Altimmune 专注于开发治疗MASH的GLP-1/glucagon双重激动剂pemvidutide [1][2] * 行业为生物制药 特别是代谢性疾病领域 如MASH 肥胖 酒精使用障碍和酒精性肝病 [1][36][38] 核心观点和论据 **药物疗效与优势** * 24周二期数据显示出类领先的MASH缓解率 以及纤维化改善的明确迹象 所有评估指标均指向药物的快速强效活性 [2][5] * 药物显示出强劲的减重效果 24周时体重减轻约6% 并且减重趋势仍在持续 未出现平台期 [2][20] * 药物具有多重作用机制 结合了glucagon的直接肝脏作用和GLP-1的代谢益处 可多方位治疗MASH 对血清脂质和血压等也有益处 [2][3][29] * 药物起效迅速 在非侵入性测试中早期就显示出变化 例如肝脂肪减少在12周时已与24周时相当 ALT改善在第4周就具有统计学显著性 [12][23] **耐受性与患者依从性** * 药物耐受性良好 在MASH研发药物中拥有最低的不良事件停药率 且无需剂量滴定 [3][12] * 良好的耐受性和早期疗效对于维持患者治疗依从性至关重要 而当前其他GLP-1药物存在高停药率问题 [14][15][16] **监管策略与三期试验设计** * 公司的基本策略是以基于活检的终点进入三期试验 但同时为监管变化预留灵活性 如采用AI组织学评估或非侵入性测试终点 [11][25][26] * 预计FDA会要求为期52周的三期试验终点和安全性数据 但非侵入性测试可以更早显示疗效 [22][23] * 采用AI评估和非侵入性测试可使试验更高效 成功概率更高 成本更低 [27] **市场定位与竞争格局** * 药物定位为可治疗从F1到F4的广泛MASH患者 结合了直接肝脏作用和减重益处 相比需要联合两种疗法的方案 单一分子更具优势 [32][34] * 与semaglutide相比 pemvidutide起效更快 72周的起效时间对于会进展为肝硬化的患者群体来说难以接受 [13][33] * 公司战略是专注于治疗MASH等具有高价值的难治性疾病 而非直接竞争肥胖适应症 肥胖是作为共病被治疗 [38] 其他重要内容 **AI组织学评估进展** * 欧洲已批准使用AI方法读取活检切片 提供该分析服务的PathAI公司已向FDA提交提案 预计FDA将在今年第四季度做出回应 [8][9] * AI评估被认为比人眼更准确 公司对此持乐观态度 并已获得优秀的AI读取结果 [8][9] **其他研发管线** * 公司在酒精使用障碍领域拥有快速通道资格 预计该试验将在2026年下半年读出结果 [36] * 酒精性肝病研究也已开始 对成功抱有高度信心 [36] **财务状况与合作** * 公司正在改善资产负债表 并评估所有选项为三期试验提供资金 [39] * 大型药企对MASH领域的兴趣回归 公司是战略讨论的一部分 但未透露具体细节 [29][31]

LOS ANGELES--(BUSINESS WIRE)--Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT. ...

PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) --  Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class ...

公司管理层任命 - Altimmune公司任命Christophe Arbet-Engels博士为首席医疗官，自2025年10月1日起生效 [1] - 新任首席医疗官拥有超过30年的行业、学术界和私人执业经验，将领导pemvidutide的临床开发，包括计划中的MASH三期试验 [1] - 前任首席医疗官Scott Harris博士将作为高级战略顾问留任至2026年2月 [1] 新任首席医疗官的背景与经验 - 新任首席医疗官在X4 Pharmaceuticals任职期间，为2024年获批用于WHIM综合征的Xolremdi（mavorixafor）的成功监管流程做出了广泛贡献，并领导了mavorixafor治疗慢性中性粒细胞减少症的后期临床项目 [2] - 其职业生涯早期曾在Biogen、勃林格殷格翰、罗氏、默克研究实验室等多家公司担任高级医学和临床职位，领导了包括LANTUS®和JARDIANCE®在内的多种产品的临床开发、注册、上市和生命周期管理工作 [2] - 新任首席医疗官持有法国巴黎大学的内科和内分泌学/代谢医学博士和博士学位，并完成了罗格斯大学的MBA学位 [2] 公司核心产品管线 - Altimmune是一家后期临床阶段的生物制药公司，专注于开发用于肝脏和心血管代谢疾病的新型肽类疗法 [6] - 公司的核心产品候选药物是pemvidutide，一种GLP-1/胰高血糖素双受体激动剂，用于治疗MASH、酒精使用障碍、酒精相关肝病和肥胖症 [6] - pemvidutide在MASH领域的IMPACT试验即将获得48周数据，同时正在进行酒精使用障碍和酒精相关肝病的二期试验 [2] 管理层股权激励 - 作为任命的一部分，新任首席医疗官将获得总计45万股普通股期权和15万股限制性股票单位（RSU） [3] - 期权行权价将基于2025年10月1日公司普通股的收盘价确定 [3] - 期权和RSU将分四年归属，其中四分之一在授予日一周年时归属，其余部分在此后按月或按年分期归属 [4][5]